Cue Biopharma, Inc.

Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study Primary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profile Clinically different efficacy profile observed relative to XOLAIR® (omalizumab) highlights potential for a […] The post Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria appeared first on CUE Biopharma.

Announced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applications Completed a $50 million private placement (PIPE) to further fund clinical development and the portfolio with significant potential for value-inflection Strengthened the leadership team with the appointments of the Chief Medical Officer and Head of R&D and the Chief […] The post Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights appeared first on CUE Biopharma.

Veteran biotech finance executive joins Cue to support the Company’s next phase of clinical and corporate growth as the company advances regulatory filing for food allergy BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. […] The post Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission appeared first on CUE Biopharma.

Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases BOSTON, July 13, 2026 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head […] The post Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development appeared first on CUE Biopharma.

BOSTON, July 09, 2026 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 1,418,071 shares of common […] The post Cue Biopharma Announces $50.0 Million Private Placement appeared first on CUE Biopharma.

Daniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board Viola Meehan, former CFO with broad experience in governance, strategic finance and executive leadership joins the board  BOSTON, June 02, 2026 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a precision immuno-engineering company focused on developing transformative […] The post Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution appeared first on CUE Biopharma.

Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expertise in precision immunoengineering Enhanced the company’s portfolio with an exclusive license for, CUE-221, a Phase 2 program targeting allergic disease Hosted virtual R&D day showcasing CUE-401, a bifunctional IL-2 and TGF-B program targeting autoimmune disease Strengthened the company’s balance sheet and ability […] The post Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments appeared first on CUE Biopharma.

BOSTON, May 07, 2026 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its newly appointed president and chief executive officer, Shao-Lee Lin, M.D., Ph.D. The equity awards were made pursuant to the Company’s 2026 Inducement Stock Incentive […] The post Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) appeared first on CUE Biopharma.

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, announced today that it has entered into a securities purchase agreement with certain accredited investors for […] The post Cue Biopharma Announces $30 Million Private Placement appeared first on CUE Biopharma.

Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases Cue Biopharma plans to initiate global Phase 2b trial in food allergy following anticipated results in 2H 2026 from Ascendant Health-led Phase 2 study in chronic spontaneous urticaria Transaction establishes Cue Biopharma as a clinical-stage company with a robust portfolio […] The post Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody appeared first on CUE Biopharma.